Systematic evaluation and meta-analysis of Herceptin® (trastuzumab) in the treatment and care of breast cancer
Abstract
Breast cancer remains the most prevalent malignancy among women worldwide and poses both biomedical and psychosocial challenges. Trastuzumab (Herceptin®), a monoclonal antibody targeting the HER2 receptor, has transformed the prognosis of patients with HER2-positive disease. This systematic review and meta-analysis synthesized data from 19 eligible studies including 9735 patients to evaluate trastuzumab’s efficacy, safety, and implications for patient care. The pooled analysis demonstrated significant improvements in overall survival, disease-free survival, progression-free survival, and overall response rate compared with standard therapy, with hazard ratios consistently favoring trastuzumab. Most adverse effects were mild to moderate, though cardiac toxicity remains a critical concern requiring vigilant monitoring. Beyond these biomedical outcomes, the findings carry important psycho-oncological implications: improved survival helps reduce fear of recurrence and psychological distress, while manageable toxicity and supportive nursing care enhance treatment adherence and quality of life. These results underscore trastuzumab’s dual role as both a therapeutic cornerstone and a psychosocially meaningful intervention. Future research should integrate patient-reported outcomes, resilience measures, and cost-effectiveness analyses to ensure that survival benefits translate into comprehensive improvements in the lived experiences of patients with breast cancer. Such integration will help position trastuzumab not only as a biomedical intervention but also as a psycho-oncological strategy to support holistic survivorship.
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Gajalakshmi P, Priya MK, Pradeep T, et al. Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium. Toxicology and Applied Pharmacology. 2013;269(2):121-131. doi:10.1016/j.taap.2013.03.011
3. Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertility Research and Practice. 2016;2(1):14. doi:10.1186/s40738-016-0029-2
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. doi: 10.1126/science.3798106
5. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet. 2013;382(9897):1021-1028. doi:10.1016/S0140-6736(13)61094-6
6. Swain SM, Clark E, Baselga J. Treatment of HER2-positive metastatic breast cancer. The New England Journal of Medicine. 2015;372(20):1964. doi:10.1056/NEJMc1503446
7. Gayathiri E, Mahalakshmi P, Pratheep T, et al. In silico and in vitro approaches to evaluate the bioactivities of Chaetomorpha linum. South African Journal of Botany. 2022;151:581-590. doi:10.1016/j.sajb.2022.06.067
8. Ji L-W, Jing C-X, Zhuang S-L, Pan W-C, Hu X-P. Effect of age at first use of oral contraceptives on breast cancer risk: An updated meta-analysis. Medicine. 2019;98(36):e15719. doi:10.1097/MD.0000000000015719
9. Wang RY, Zhang Y, Gao Z, Wang X. Role of sonoelastography in assessment of axillary lymph nodes in breast cancer: a systematic review and meta-analysis. Clinical Radiology. 2020;75(4):320. e1-320. e7. doi:10.1016/j.crad.2019.11.016
10. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews. 2012;(4)doi:10.1002/14651858.CD006243.pub2
11. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730
12. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. Journal of Clinical Oncology. 2010;28(7):1138-1144. doi:10.1200/JCO.2009.24.2024
13. Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5
14. Lambertini M, Fontanella C. How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer? Breast Cancer Research and Treatment. 2018;168(3):773-774. doi:10.1007/s10549-017-4654-1
15. Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment. 2019;173(1):37-48. doi:10.1007/s10549-018-4921-9
16. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology. 2005;23(19):4265-4274. doi:10.1200/JCO.2005.04.173
17. de Haas SL, Slamon DJ, Martin M, et al. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine+ pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Research. 2023;25(1):2. doi:10.1186/s13058-022-01587-z
18. Helgeson VS, Snyder P, Seltman H. Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change. Health Psychology. 2004;23(1):3. doi:10.1037/0278-6133.23.1.3
19. Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Supportive Care in Cancer. 2009;17(3):241-251. doi:10.1007/s00520-008-0444-y
20. Vamsi KB, Glory TJ, Florida T, Aneesh N, Rekha L, Thangaraj P. Gene expression analysis of EGFR and PI3K genes in A549 lung cancer cell line treated with Withania somnifera root extract. Research Journal of Biotechnology Vol. 2020;15(2).
21. Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. JNCI: Journal of the National Cancer Institute. 2021;113(12):1648-1669. doi:10.1093/jnci/djab131
22. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72(1). doi:10.3322/caac.21708.
23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine. 2005;353(16):1659-1672. doi:10.1056/NEJMoa052306
24. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
25. Von Minckwitz G, Procter M, De Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. New England Journal of Medicine. 2017;377(2):122-131. doi:10.1056/NEJMoa1703643
26. Hershman DL, Tsui J, Wright JD, et al. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. Journal of Clinical Oncology. 2015;33(9):1053-1059. doi:10.1200/JCO.2014.58.3062
27. Tucker PE, Cohen PA, Bulsara MK, et al. The impact of bilateral salpingo-oophorectomy on sexuality and quality of life in women with breast cancer. Supportive Care in Cancer. 2021;29(1):369-375. doi:10.1007/s00520-020-05503-z
28. Fann JR, Thomas-Rich AM, Katon WJ, et al. Major depression after breast cancer: a review of epidemiology and treatment. General Hospital Psychiatry. 2008;30(2):112-126. doi:10.1016/j.genhosppsych.2007.10.008
29. Arving C, Sjode P-O, Bergh J, et al. Individual psychosocial support for breast cancer patients: A randomized study of nurse versus psychologist interventions and standard care. Cancer Nursing. 2007;30(3):E10-E19. doi:10.1097/01.NCC.0000270709.64790.05
30. Antoni MH, Lehman JM, Kilbourn KM, et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychology. 2001;20(1):20. doi:10.1037/0278-6133.20.1.20
31. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122
32. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nature Reviews Cardiology. 2010;7(10):564-575. doi:10.1038/nrcardio.2010.121
33. Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. The Breast. 2022;62:S12-S16. doi:10.1016/j.breast.2022.01.006
34. Seidman AD, O'Shaughnessy J, Misset J-L. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? The Oncologist. 2002;7(S6):20-28. doi:10.1634/theoncologist.7-suppl_6-20
35. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Seminars in Oncology. 2001;28(Supplement3):13-19. doi:10.1016/S0093-7754(01)90188-5
36. Chen X, Guo Y, Wang P, et al. Efficacy and safety of adrenergic beta-antagonist combined with lasers in the treatment of infantile hemangiomas: A meta-analysis. Pediatric Surgery International. 2020;36(10):1135-1147. doi:10.1007/s00383-020-04711-2
